Journals / Retina-Vitreus / 2019 / Cilt: 28 - Sayı: 3

The Effect of Afl ibercept on Ganglion Cell Complex in Neovascular AgeRelated Macular Degeneration

Neovasküler Yaşa Bağlı Makula Dejenerasyonunda Afl ibercept Enjeksiyonunun Gangliyon Hücre Kompleksi Üzerine Etkisi

Pages
285–288
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mean GCC thickness was 93.20 μm before injection and 92.56 μm at 6 months. (P = 0.250) Conclusion: It was found that intravitreal Afl ibercept injection did not have a signifi cant effect on GCC thickness after 6 months of follow-up.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose:To evaluate ganglion cell complex (GCC) thickness in patients with neovascular age-related macular degeneration (AMD) who underwent afl ibercept injection by using optical coherence tomography (OCT).
📊
Key Findings & Data:Methods:The study included 28 eyes of 28 patients with neovascular AMD who had at least 6 months of follow-up following 3-dose antiVEGF injection.
💡
Conclusion & Impact:Mean GCC thickness was 93.20 μm before injection and 92.56 μm at 6 months. (P = 0.250) Conclusion: It was found that intravitreal Afl ibercept injection did not have a signifi cant effect on GCC thickness after 6 months of follow-up.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose:To evaluate ganglion cell complex (GCC) thickness in patients with neovascular age-related macular degeneration (AMD) who underwent afl ibercept injection by using optical coherence tomography (OCT). Methods:The study included 28 eyes of 28 patients with neovascular AMD who had at least 6 months of follow-up following 3-dose antiVEGF injection. Central macular thickness (CMT) and GCC thickness were evaluated with SD-OCT. Visual acuity, intraocular pressure, CMT, GCC thickness were recorded at the fi rst month, 3 months and 6 months after the injection. Results:The mean age of the patients was 71.9 ± 7.2 (55-82) years. Best corrected visual acuity (logMAR) before injection was 0.90±0.24, at third month it was 0.32±0.22 idi (p=0.005). Before injection the mean CMT was 383.75 ± 28.6 μm, it was 267 ± 67 μm in the 6th month (p = 0.001). Mean GCC thickness was 93.20 μm before injection and 92.56 μm at 6 months. (P = 0.250) Conclusion: It was found that intravitreal Afl ibercept injection did not have a signifi cant effect on GCC thickness after 6 months of follow-up. Afl ibercept is an effective, reliable treatment option in the treatment of neovascular AMD.

Özet

Amaç: Afl ibercept injeksiyonu uygulanan neovasküler yaşa bağlı makula dejenerasyonu (YBMD) hastalarında optik koherens tomografi (OKT) ile gangliyon hücre kompleksini (GHK) değerlendirmek. Gereç-Yöntem: Çalışmaya dahil edilme kriterlerine uyan, 3 doz yükleme anti-VEGF enjeksiyonu sonrası hastalığın stabil seyrettiği, enjeksiyon sonrası en az 6 aylık takipleri olan neovasküler YBMD tanılı 28 hastanın 28 gözü çalışmaya dahil edildi. Santral makula kalınlığı (SMK), GHK kalınlığı SD-OKT ile değerlendirildi. Hastaların enjeksiyon sonrası 1. ay, 3. ay ve 6. ayda görme keskinliği, Göz içi basıncı, SMK, GHK kalınlığı kaydedildi. Bulgular: Hastaların ortalama yaşı 71.9±7.2 (55-82) idi. En iyi düzeltilmiş görme keskinliği (logMAR) enjeksiyon öncesi; 0.90±0.24 iken, yükleme sonrası 0.32±0.22 idi.(p=0.005) Enjeksiyon öncesi SMK 383.75±28.6 μm iken, 6.ayda 267±67 μm idi.(p=0.001) Ortalama GHK kalınlığı enjeksiyon öncesi 93.20 μm iken, 6. Ayda 92.56 μm olarak saptandı. ( p=0.250) Tartışma: İntravitreal Afl ibercept tedavisinin 6 aylık takip sonrasında GHK üzerine anlamlı etkisi olmadığı saptanmış olup, Neovasküler YBMD tedavisinde afl ibercept etkili, güvenilir bir tedavi seçeneğidir.

🔖

Cite This Article

ÇİLOĞLU, E., DOĞAN, N. Ç. (2019). The Effect of Afl ibercept on Ganglion Cell Complex in Neovascular AgeRelated Macular Degeneration. Retina-Vitreus, Cilt: 28 - Sayı: 3, 285–288. https://ajindex.com/articles/304806

References (13)

  1. Schmidht-Erfurth V, Chang V, Lowenstein A et al. European Society of retina Specialists. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).Br J Ophthalmol 2014;98:1144-67.
  2. Storkebaum E, Lambrechts D, Carmeliet P. “VEGF:once regarded as a specifi c angiogenic factor,now implicated in neuroprotection’’. BioEssays 2004;26(9):943-54.
  3. Koh VT, Tham YC, Cheung YC, et al. Determinants of ganglion cell-inner pleksiform layer tickness masured by high-defi nition optical coherence tomography. Invest Ophthalmol Vis Sci 2012;53:5853-9
  4. Nishijima K, Ng YS, Zhang L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53-67
  5. Madeira MH, Boia R, Santos PF, et al. Contribution of microgliamediated neuroinfl ammation to retinal degenerative diseases. Mediators Infl amm 2015;2015:673090. Kent D. The stereotypical molecular cascade in neovascular agerelated macular degeneration:the role of dynamic reciprocity. Eye (Lond) 2015;29:1416-26.
  6. Meyer-Rüsenberg B, Pavlidis M, Stupp T, et al. Pathological changes in human retinal ganglion cells associated with diabetic and hypersensitive retinopathy. Graefes Arch Clin Exp Ophthalmol 2007;245(7):1009-18.
  7. Lee EK, Yu HG. Ganglion cell- inner plexiform layer and peripapillary retinal nerve fi bre layer thicknesses in age-related macular degeneration. Invest Ophthalmol Vis Sci 2015;56:3976-83.
  8. Zucchiatti I, Parodi MB, Pierro L, et al. Macular Ganglion Cell Complex and Retinal Nerve Fiber Layer Comparison in Different Stages of Age-Related Macular Degeneration. Am J Ophthalmol 2015;160(3):602-7.
  9. Rimayanti U, Kiuchi Y, Yamane K, et al. Inner retinal layer comparisons of eyes with exudative age-related macular degeneration and eyes with age-related macular degeneration and glaucoma. Graefes Arch Clin Exp Ophthalmol 2014;252:563-70.
  10. Yenice E, Sengun A, Demirok G, et al. Ganglion cell complex thickness in nonexudative age-related macular degeneration. Eye 2015;29:1076-80.
  11. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin) Retina 2007;27(8):1044-7.
  12. Kim JE, Mantravadi AV, Hur EY, et al. Short term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008;146(6):930-4.
  13. Sharei V, H